Aripiprazole once-monthly shows superior effectiveness to

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Aripiprazole once-monthly shows superior effectiveness to paliperidone palmitate once-monthly on quality of life scale in patients with schizophrenia
  • The head-to-head QUALIFY study compared the effectiveness of aripiprazole once-monthly to paliperidone palmitate once-monthly in adult patients with schizophrenia
  • Patients treated with aripiprazole once-monthly demonstrated a statistically significant improvement on the primary endpoint, quality-of-life measure, compared to those treated with paliperidone palmitate
  • Discontinuations due to adverse events occurred in 10.8% of patients in the aripiprazole once-monthly group compared to 18.4% of patients in the paliperidone once-monthly group

Valby, Denmark and Princeton, N.J., U.S., 3 November 2014 - H. Lundbeck A/S (Lundbeck) and Otsuka America Pharmaceutical Inc. (Otsuka) today announced results from the QUALIFY study [i] ; the first study of its kind comparing two atypical long-acting injectable anti-psychotic therapies in a close-to-real life setting. The effectiveness of aripiprazole (aripiprazole extended-release injectable suspension, for intramuscular use, Abilify Maintena ® ) and paliperidone palmitate once-monthly (paliperidone palmitate extended-release injectable suspension, for intramuscular use) in adult patients with schizophrenia was measured by the Heinrichs-Carpenter Quality of Life Scale (QLS; primary endpoint). QLS is clinician-rated scale designed to evaluate social functioning and behaviour in patients with schizophrenia.

The QLS is one of the most commonly used quality-of-life scales in schizophrenia clinical trials. The four domains of the QLS evaluate the patient’s intrapsychic foundations (sense of purpose, motivation, emotional interaction, etc.); interpersonal relations (social activity, social network, etc.) instrumental role (work functioning, work satisfaction, etc.); and common objects and activities. Higher scores indicate better quality of life [ii] . Additional secondary assessments include the Clinical Global Impressions scales (CGI, which measures symptom severity and treatment response), the Investigator’s Assessment Questionnaire (IAQ, designed to evaluate response to antipsychotics) and the Subjective Well-being under Neuroleptic Scale – short version (SWN-S, a self-rating scale for patients on antipsychotic drugs).

In a 28 week trial, patients treated with aripiprazole once-monthly demonstrated a statistically significant improvement in the QLS total score compared to patients treated with paliperidone palmitate once-monthly. The mean difference between treatments of the change from baseline to week 28 in QLS total score was 4.4 (p=0.031) with a respective change of 7.5 for the aripiprazole once-monthly group and 3.1 for the paliperidone once-monthly group.

A difference between treatments was also confirmed by a change in the Clinical Global Impression-Severity Scale (CGI-S, used by clinicians to evaluate the severity of a patient’s illness) from baseline to 28 weeks of treatment (p=0.004). Both treatments were generally well-tolerated, however discontinuation rates due to adverse events were 10.8% (n=16/148) vs. 18.4% (n=27/147), for aripiprazole once-monthly group vs paliperidone once monthly group, respectively [iii] .

About the QUALIFY study

QUALIFY is a randomized, open-label rater-blinded, head-to-head comparison of intramuscular aripiprazole once-monthly (400 or 300 mg/month) and intramuscular paliperidone palmitate injection (50 to 150 mg/month (EU) or 78 to 234 mg/month (US and Canada)) over 28 weeks. The study was designed as a non-inferiority study, allowing for subsequent superiority testing, if non-inferiority criterion was met. After a minimum of 3-week oral conversion period where patients received either oral aripiprazole or oral paliperidone, the intramuscular formulations were administered according to the prescribing information for five weeks and continued for 20 weeks. The primary endpoint was the QLS total score change from baseline to week 28. The study randomized 295 patients in Europe and North America of which 281 received study treatment.

The study design was presented at the New Clinical Drug Evaluation Unit (NCDEU) 53 rd Annual Meeting in May 2013 [iv] . Data from the QUALIFY study will be presented at upcoming medical congresses and in scientific publications.

About Abilify Maintena (aripiprazole once-monthly)

Abilify Maintena (aripiprazole once-monthly) is the first and only once-monthly injection of a dopamine D2 partial agonist. It is available in a number of European countries for maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole. Furthermore, it is available in the US for the treatment of schizophrenia. In Canada it is available for the maintenance treatment of schizophrenia in stabilised adult patients and in Australia for maintenance of clinical improvement in the treatment of schizophrenia. 

About schizophrenia

Schizophrenia is a disease characterized by a distortion in the process of thinking and of emotional responsiveness. It most commonly manifests as hallucinations, paranoid or bizarre delusions, or disorganized speech and thinking, and is accompanied by significant social or occupational dysfunction. Onset of symptoms typically occurs in young adulthood and the condition is chronic, often requiring life-long treatment to mitigate symptoms. It has been estimated that schizophrenia affects approximately 1% of the adult population in the US, and approximately 24 million people worldwide [v] , [vi] . In the US, there are approximately 2.4 million adults with schizophrenia, prevalent equally in both genders [vii] , [viii] . While there is no cure for the disease, symptoms and risk of relapse—the re-emergence or worsening of psychotic symptoms [ix] — can be managed in most patients with appropriate antipsychotic treatment.

Otsuka contacts

Investors: Media:
   
Yoko Ishii Rose Weldon
Otsuka Holdings Co., Ltd. Otsuka America Pharmaceuticals, Inc.
Ishiiyo@Otsuka.jp rose.weldon@otsuka-us.com
+81 3 6361 7411 +1 609 524 6879
   

Lundbeck contacts

Investor s: Media:
   
Palle Holm Olesen Mads Kronborg
Vice President,  Investor Relations Director, Media Relations
PALO@lundbeck.com MAVK@lundbeck.com
+45 36 43 24 26 +45 36 43 30 00
   
Jens Høyer Ashleigh Nicole Duchene
Specialist, Investor Relations Senior Manager, Communication
JSHR@lundbeck.com ADUC@lundbeck.com
+45 36 43 33 86 +1 847 282 1164
   

About Otsuka America Pharmaceuticals, Inc.

Otsuka America Pharmaceutical, Inc. (OAPI) is an innovative, fast-growing healthcare company that commercializes Otsuka-discovered and in-licensed products in the U.S., with a strong focus on neuroscience, oncology, cardio-renal and medical devices. For more information, visit http://www.otsuka-us.com .

OAPI is a subsidiary of Otsuka America, Inc. (OAI), a holding company established in the U.S. in 1989. OAI is wholly owned by Otsuka Pharmaceutical Co., Ltd, based in Japan. The Otsuka Group employs approximately 42,000 people globally and its products are available in more than 80 countries worldwide. Otsuka welcomes you to visit its global website at https://www.otsuka.co.jp/en/.

About Lundbeck

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in brain diseases. For more than 50 years, we have been at the forefront of research within neuroscience. Our key areas of focus are alcohol dependence, Alzheimer’s disease, bipolar disorder, depression/anxiety, epilepsy, Huntington’s disease, Parkinson’s disease, schizophrenia, stroke and symptomatic neurogenic orthostatic hypotension (NOH).

An estimated 700 million people worldwide are living with brain disease and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain disease – we call this Progress in Mind.

Read more at www.lundbeck.com/global/about-us/progress-in-mind .

Our approximately 6,000 employees in 57 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several late-stage development programmes and our products are available in more 100 countries. We have research centres in China, Denmark and the United States and production facilities in China, Denmark, France and Italy. Lundbeck generated revenue of approximately DKK15.3 billion in 2013 (EUR2.1 billion; USD2.7 billion).

Lundbeck’s shares are listed on the stock exchange in Copenhagen under the symbol ”LUN”. Lundbeck has a sponsored Level 1 ADR program listed in the US (OTC) under the symbol ”HLUYY”. For additional information, we encourage you to visit our corporate site www.lundbeck.com .

Safe Harbor/Forward-Looking Statements

The above information contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance.

Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include interest rate and currency exchange rate fluctuations, delay or failure of development projects, production problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, and unexpected growth in costs and expenses.

Certain assumptions made by Lundbeck are required by Danish Securities Law for full disclosure of material corporate information. Some assumptions, including assumptions relating to sales associated with product that is prescribed for unapproved uses, are made taking into account past performances of other similar drugs for similar disease states or past performance of the same drug in other regions where the product is currently marketed. It is important to note that although physicians may, as part of their freedom to practice medicine in the US, prescribe approved drugs for any use they deem appropriate, including unapproved uses, at Lundbeck, promotion of unapproved uses is strictly prohibited.

[i] Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients with Schizophrenia. ClinicalTrials.gov. 2014. Available at: https://clinicaltrials.gov/ct2/show/NCT017955...amp;rank=1. Accessed on Oct. 28, 2014.

[ii] Heinrichs, D., et al. The Quality of Life Scale: An Instrument for Rating the Schizophrenic Deficit Syndrome. Schizophrenia Bulletin. 1984; 10: 388-396.

[iii] Data on File: 14724A – the QUALIFY study.

[iv] Hansen, K., Baker R., Peters-Strickland T., Forray C., Nylander AG., Eramo A.: “Assessing the Effectiveness of Aripiprazole Once-monthly vs. Paliperidone Palmitate for the Long-term Treatment of Schizophrenia”. Poster from NCDEU2013.

[v] National Institute of Mental Health (NIMH). Health Topics: Statistics. Available at http://www.nimh.nih.gov/statistics/1SCHIZ.shtml. Accessed May 14, 2013.

[vi] World Health Organization (WHO). Schizophrenia Fact Sheet. 2010. Available at http://www.who.int/mental_health/management/s...hrenia/en/. Accessed May 14, 2013.

[vii] National Institutes of Mental Health (NIMH). The Numbers Count: Mental Disorders in America. Available at http://www.nimh.nih.gov/health/publications/t...ndex.shtml. Accessed May 14, 2013.

[viii] Regier, Darrel et al. The de Facto US Mental and Addictive Disorder Service System. Archives of General Psychiatry. 1993; 50: 85-94.

[ix] Almond, S et al. Relapse in schizophrenia: costs, clinical outcomes and quality of life. British Journal of Psychiatry, 2004; 184: 346-351.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Berlin Heals Puts Microcurrent Therapy to a Real Test

Updated Category News Views 26

A silent electrical signal is heading into the sort of trial that separates intriguing ideas from credible medical evidence. Berlin Heals Holding AG has initiated C-MIC IV, an international randomized, double-blind, sham-controlled study of its implanted microcurrent therapy for symptomatic heart failure. The first patient has already been implanted in Kragujevac, Serbia....

Continue Reading
Modexus Opens a $500 Million Buyback With Real Caveats

Updated Category News Views 68

A half-billion-dollar buyback authorization can make a stock crowd sit up fast, and Modexus Solutions has plainly chosen that moment. On November 18, 2026, the Racine, Wisconsin-based thermal-management company said its board authorized repurchases of up to $500 million of common stock. For holders of NYSE:MOD, that is a meaningful declaration of intent. It says...

Continue Reading
LRM Adds Two IND Studies Testing Injectable PDGF in Skin

Updated Category News Views 9

Under-eye medicine has a nasty habit of outrunning the evidence, which makes LRM's decision to put injectable rhPDGF-BB through more formal study worth watching. Lynch Regenerative Medicine has announced two FDA-accepted INDs for investigator-initiated clinical trials: one examining what the material does inside facial skin, the other testing it for infraorbital...

Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools

Updated Category News Views 187

Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...

Continue Reading
Perform.AI Tests Whether Stores Can Sell to Agents

Updated Category News Views 39

Shopping bots are about to become one more fussy customer standing in the aisle, except this one reads machine-facing files, rejects broken checkout steps, and does not care how pretty the homepage looks. Perform.AI has launched a free UCP and ACP Readiness Checker aimed at online retailers that need to know whether AI agents can find products, purchase them, and follow...

Continue Reading
Fidelis Puts $140,000 Behind Statewide Postpartum Care

Updated Category News Views 35

A missed postpartum appointment can look like a small administrative failure until it is not. Fidelis Care’s $140,000 round of Here for Your Health maternal health grants is aimed squarely at that unglamorous but consequential gap: keeping new mothers connected to care after delivery, particularly in underserved New York communities. Small Dollars, Very Specific...

Continue Reading
Aurora Innovation Faces Legal Probe After Stock Plunge

Updated Category News Views 182

Aurora's Troubles Draw Legal Scrutiny Looks like Aurora Innovation’s in the hot seat again, and not in a good way. When you see Kessler Topaz Meltzer & Check, LLP throwing their name into the mix, you know it’s getting serious. This legal eagle firm is poking around, seeing if Aurora stepped over the line with investors after their latest stumble—a production delay...

Continue Reading
Voranigo Follow-Up Deepens the Glioma Care Debate Today

Updated Category News Views 159

Brain-tumor progress rarely arrives with a clean victory lap, but the longer INDIGO readout gives clinicians and sector watchers something sturdier than a one-time headline. Servier presented extended Phase 3 results for VORANIGO, or vorasidenib, at the Society for Neuro-Oncology meeting in Philadelphia on November 14 and 15, 2026. The central message is durable benefit...

Continue Reading
Texas Restaurants Get a New Read on Customer Demand

Updated Category News Views 148

Texas restaurant owners are being handed a sharper flashlight, and frankly it is overdue. HundredX and the Texas Restaurant Association have launched a pilot that gives TRA members access to the HundredX Restaurant Insights Platform, aiming to bring customer and market intelligence to the independent operators and regional chains that usually cannot pay big-company prices...

Continue Reading
Knowles Expands Its Teacher Pipeline With 39 Fellows

Updated Category News Views 32

Thirty-Nine Teachers Is Not a Trivial Signal Thirty-nine new math and science teachers may not rattle public markets, but it says plenty about where the real strain sits in American education. The Knowles Teacher Initiative has named its 2026 Teaching Fellowship class, its largest ever, and the timing is dead serious: schools are still wrestling with recruiting and...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation into GoHealth, Inc. Sparks Investor Concerns

Updated Category News Views 354

GoHealth, Inc. Under Investigation for Alleged Securities Fraud Pomerantz LLP has initiated an investigation regarding potential claims involving investors of GoHealth, Inc. (NASDAQ: GOCO). This probe aims to determine whether the company and some of its executives have participated in misleading practices concerning their financial statements. The firm is reaching out to...

Continue Reading
Exploring the Features of the 2026 Toyota GR Corolla

Updated Category News Views 334

Unleashing the Adventure with the 2026 Toyota GR Corolla Get ready for an adventurous experience with the all-new 2026 Toyota GR Corolla. Engineered to perfection, this vehicle is equipped with the innovative GR-FOUR All-Wheel Drive System, making it a formidable companion whether you're racing on the track or maneuvering through rugged terrains. The GR Corolla is...

Continue Reading
Tandem Diabetes Care Boosts Sales Guidance After Q3 Success

Updated Category News Views 65

Tandem Diabetes Care Reports Impressive Q3 Financial Results Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading name in insulin delivery and diabetes management technology, has reported its financial accomplishments for the third quarter of 2024. Following an exceptional performance, the company has also increased its sales guidance for the upcoming fiscal year. Key...

Continue Reading
Green IT Services Growth: A Comprehensive Market Overview

Updated Category News Views 193

Green IT Services Market: A Dynamic Overview The evolution of technology is more than just a trend; it represents a paradigm shift towards sustainability. As organizations embrace digital transformation, the focus on Green IT services has rapidly gained importance. The latest analyses indicate that the Green IT Services market, valued at USD 18.8 billion in recent years,...

Continue Reading
Duke Energy's Response to Hurricane Helene's Aftermath

Updated Category News Views 558

Hurricane Helene Aftermath and Power Restoration Efforts Following the severe impact of Hurricane Helene, Duke Energy (NYSE: DUK) has made remarkable progress in restoring electrical services to over 2.16 million customers. Despite these extensive restoration efforts, around 334,000 customers are still without power, largely in Upstate South Carolina and the mountainous...

Continue Reading